European Journal of Nuclear Medicine and Molecular Imaging

Professor Ogawa, Mr. Echigo (PhD student), and their colleagues in Kanazawa University report in Eur J Nucl Med Mol Imaging that combination of an At-211-labeled agent with immune checkpoint blockade significantly enhances its therapeutic effect. This strategy represents a promising advancement in the development of next-generation cancer therapies that combine targeted alpha therapy and immunotherapy.

Researchers from Osaka University and Dusseldorf University have found a new theranostic compound that effectively shrinks prostate tumor in mice. Theranostics is a cancer treatment that involves finding cancer cells anywhere in the body and delivering targeted radiation to kill those cells, by drugs that contain radioactive isotopes. It means that this compound could be a promising option for treating hormone-resistant metastases in patients with recurrent cancers. This is stated to be tested in an upcoming clinical trial.